Primary Menu

The GPCR Consortium is a not for profit entity formed to bring together industry and academic scientists to advance GPCR research for drug development. The goal of the GPCR Consortium is to generate high-resolution pictures of hundreds of medically important GPCRs.

The human body is controlled by 826 GPCRs, which are involved in a wide variety of human physiology and are implicated in many diseases. As a drug target, GPCRs are highly valuable but mechanistically poorly understood and with limited structural information that could greatly aid in finding new drug candidates.

Amgen (United States), Sanofi (Europe) and ONO (Japan) are the founding industry members of the GPCR Consortium. The GPCR Consortium hopes to attract up to five additional industry members to achieve the goal of determining structures of 200 of the 826 known human GPCRs, prioritized in disease areas that initially include diabetes, cancer, and mental disorders.

The GPCR Consortium is data-centric, with the primary objective being dissemination of protein structural coordinates, reagents and supporting data to both the consortium members and the broader scientific community. All research outputs such as three-dimensional structures of GPCRs and constructs will be compiled and placed in the public domain. The consortium members contribute chemical compounds and nominate GPCR targets prioritized in disease areas.

The GPCR Consortium was started by Professor Raymond Stevens, who is focused on the structure and function of GPCRs and human cell signaling, and is coordinated by Dr. Michael Hanson, a leader in GPCR structural biology.

For more information or if you are interested in joining the GPCR Consortium, please contact us.